Nautilus Biotechnolgy (NAUT) Stock Statistics & Valuation Metrics

Nautilus Biotechnolgy has a market cap or net worth of $294.90M. The enterprise value is $320.12M.

Nautilus Biotechnolgy has 126,564,476 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nautilus Biotechnolgy’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -35.74%.

The current PE Ratio of Nautilus Biotechnolgy is ―. Nautilus Biotechnolgy’s PEG ratio is 0.26.

In the last 12 months, Nautilus Biotechnolgy had revenue of 0.00 and earned -59.00M in profits. Earnings per share was -0.47.

In the last 12 months, operating cash flow was -50.70M and capital expenditures -1.28M, giving a free cash flow of -51.97M billion.

Nautilus Biotechnolgy pays an annual dividend of ―, resulting in a dividend yield of ―

Nautilus Biotechnolgy upcoming earnings date is May 5, 2026, Before Open (Confirmed).

Nautilus Biotechnolgy as a current ratio of 13.33, with Debt / Equity ratio of 19.12%

In the past 12 months, Nautilus Biotechnolgy has paid 0.00 in taxes.

Nautilus Biotechnolgy EV to EBITDA ratio is -5.02, with an EV/FCF ratio of -5.08.

Nautilus Biotechnolgy has $103.41M in cash and marketable securities with $30.02M in debt, giving a net cash position of $73.39M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Nautilus Biotechnolgy is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy